Immunotherapy and local therapies in metastatic laryngeal cancer management: a case report.

IF 1.3 Q4 ONCOLOGY

ecancermedicalscience Pub Date : 2025-07-17 eCollection Date: 2025-01-01 DOI:10.3332/ecancer.2025.1947

João Felipe Lima Feldmann, João Henrique Lima Feldmann, Cassio Murilo Hidalgo-Filho, Amanda Acioli de Almeida Robatto, Breno Jeha Araújo, Publio Cesar Cavalcante Viana, Gilberto de Castro Junior

{"title":"Immunotherapy and local therapies in metastatic laryngeal cancer management: a case report.","authors":"João Felipe Lima Feldmann, João Henrique Lima Feldmann, Cassio Murilo Hidalgo-Filho, Amanda Acioli de Almeida Robatto, Breno Jeha Araújo, Publio Cesar Cavalcante Viana, Gilberto de Castro Junior","doi":"10.3332/ecancer.2025.1947","DOIUrl":null,"url":null,"abstract":"Background: Advanced laryngeal carcinoma (LC) has a poor prognosis with limited treatment options. Managing oligometastasis is challenging, and there are currently no standard recommendations.Methods: We reported a case of a 64-year-old male with locally advanced LC who developed oligometastatic disease in the bones and liver 21 months after concurrent cisplatin-based chemoradiotherapy. Initially, due to negative PD-L1 expression, the patient was treated docetaxel, cisplatin and cetuximab combination. Chemotherapy after 10 months, new hepatic progression was confirmed by biopsy. Given the asymptomatic, single-site progression in a cirrhotic liver, microwave ablation was performed. Isolated bone progressions were treated with stereotactic body radiation therapy at 2 and 4 months, and nivolumab replaced cetuximab.Results: The patient has shown no evidence of disease progression for 22 months, with excellent tolerance.Conclusion: The synergy between nivolumab and local therapies appears promising for managing oligometastasis in laryngeal cancer.","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1947"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426497/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ecancermedicalscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3332/ecancer.2025.1947","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Advanced laryngeal carcinoma (LC) has a poor prognosis with limited treatment options. Managing oligometastasis is challenging, and there are currently no standard recommendations.

Methods: We reported a case of a 64-year-old male with locally advanced LC who developed oligometastatic disease in the bones and liver 21 months after concurrent cisplatin-based chemoradiotherapy. Initially, due to negative PD-L1 expression, the patient was treated docetaxel, cisplatin and cetuximab combination. Chemotherapy after 10 months, new hepatic progression was confirmed by biopsy. Given the asymptomatic, single-site progression in a cirrhotic liver, microwave ablation was performed. Isolated bone progressions were treated with stereotactic body radiation therapy at 2 and 4 months, and nivolumab replaced cetuximab.

Results: The patient has shown no evidence of disease progression for 22 months, with excellent tolerance.

Conclusion: The synergy between nivolumab and local therapies appears promising for managing oligometastasis in laryngeal cancer.

Abstract Image

查看原文本刊更多论文

免疫治疗和局部治疗在转移性喉癌的治疗：1例报告。

背景：晚期喉癌（LC）预后差，治疗选择有限。管理少转移是具有挑战性的，目前没有标准的建议。方法：我们报告了一例64岁男性局部晚期LC患者，在顺铂同步放化疗21个月后发生骨和肝脏少转移性疾病。最初，由于PD-L1表达阴性，患者接受多西紫杉醇、顺铂和西妥昔单抗联合治疗。化疗10个月后，活检证实肝脏有新的进展。考虑到肝硬化无症状、单部位进展，我们进行了微波消融。孤立的骨骼进展在2个月和4个月时接受立体定向放射治疗，并用纳武单抗替代西妥昔单抗。结果：患者22个月无疾病进展迹象，耐受性极佳。结论：纳武单抗与局部治疗的协同作用有望治疗喉癌的少转移。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊